Log In
Print
BCIQ
Print
Print this Print this
 

2661380, AMP-224

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionFusion protein that contains the extracellular domain of PD-1 ligand 2 (B7-DC; PDCDILG2) and the Fc-portion of IgG
Molecular Target Programmed cell death 1 ligand 2 (PD-L2) (PDCD1LG2) (B7-DC) ; Programmed cell death 1 (PD-1) (PDCD1) (CD279)
Mechanism of ActionImmune modulation
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner GlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,008.0M

$248.0M

$760.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today